Immunocore Holdings plc (IMCR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Immunocore reported revenue of $400.0M, up 29.0% from $310.2M the year before. Net income was -$35.5M (a -8.9% net margin), or -$0.71 per diluted share. Gross margin was 98.7% and operating margin was -11.3%. Operating activities generated -$10.7M of cash, leaving -$15.1M of free cash flow. At fiscal year end, Immunocore held $1.07B in total assets against $686.2M in total liabilities, including $467.7M of cash and equivalents.
Open the full interactive Immunocore financials → Quarterly statements, key ratios, valuation history and price charts.
Immunocore Key Stats
| Share Price | $27.82 |
|---|---|
| Market Cap | $1.42B |
| Revenue YoY Growth | +28.9% |
| 52-Week Range | $27.79 – $40.22 |
| Shares Outstanding | 51.0 million (basic, 2026 Q2) |
Immunocore Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $249.4M | $310.2M | $400.0M |
| Gross Profit | $248.4M | $307.5M | $394.9M |
| Operating Income | -$59.6M | -$70.5M | -$45.4M |
| Pre-Tax Income | -$60.9M | -$52.9M | -$19.1M |
| Income Tax | -$5.6M | -$1.9M | $16.4M |
| Net Income | -$55.3M | -$51.1M | -$35.5M |
| Diluted EPS | -$1.13 | -$1.02 | -$0.71 |
Immunocore Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $103.7M | $104.5M | $106.7M | $115.9M |
| Net Income | -$177,000 | -$30.1M | $13.0M | -$808,000 |
| Diluted EPS | — | -$0.60 | $0.25 | -$0.02 |
Immunocore Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $442.6M | $455.7M | $467.7M |
| Current Assets | $528.8M | $929.9M | $996.7M |
| Total Assets | $597.0M | $1.01B | $1.07B |
| Current Liabilities | $139.0M | $212.2M | $246.7M |
| Total Long-Term Debt | $100.0M | $391.0M | $393.1M |
| Total Liabilities | $228.2M | $648.8M | $686.2M |
| Shareholders' Equity | $368.8M | $360.7M | $381.0M |
Immunocore Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | $2.9M | $26.1M | -$10.7M |
| Cash From Investing | -$5.4M | -$355.1M | -$16.3M |
| Cash From Financing | $34.3M | $343.9M | $12.4M |
| Free Cash Flow | -$2.5M | $20.9M | -$15.1M |
Figures from Immunocore's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immunocore financials page for every line item.
Immunocore Company Profile
| Ticker | IMCR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Oxfordshire, United Kingdom |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001671927 |
Frequently Asked Questions
What was Immunocore's revenue in fiscal 2025?
Immunocore (IMCR) reported revenue of $400.0M for fiscal 2025.
What is Immunocore's annual revenue history?
Immunocore's annual revenue by fiscal year: 2023: $249.4M; 2024: $310.2M; 2025: $400.0M.
What was Immunocore's net income in fiscal 2025?
Immunocore reported net income of -$35.5M for fiscal 2025.
What was Immunocore's earnings per share (EPS) in fiscal 2025?
Immunocore's diluted EPS was -$0.71 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Immunocore generate in fiscal 2025?
Immunocore generated -$15.1M of free cash flow in fiscal 2025.
What was Immunocore's revenue last quarter?
In its most recent reported quarter (2026 Q2), Immunocore reported revenue of $115.9M.
How much debt does Immunocore have?
Immunocore reported $393.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Immunocore are outstanding?
Immunocore reported a weighted average of 51.0 million basic shares outstanding in 2026 Q2.
What is Immunocore's market cap?
Based on its latest closing price, Immunocore (IMCR) has a market capitalization of about $1.42B.
When does Immunocore's fiscal year end?
Immunocore's fiscal year end, as registered with the SEC, is December 31.
Where is Immunocore headquartered?
Immunocore lists its business address in Oxfordshire, United Kingdom in its SEC filings.
Immunocore Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →